Chart your patients’ course with
a once-yearly administration

The recommended dose of VANTAS is one implant for 12 months

Each implant contains 50 mg histrelin acetate

The implant is inserted subcutaneously in the inner aspect of the upper arm and provides continuous release of histrelin for 12 months of hormonal therapy

VANTAS must be removed after the 12 months of therapy. At the time of removal, another implant may be inserted to continue therapy.

Insertion of the VANTAS implant—an in-office, surgical procedure—requires local anesthetic, a small incision, and just a few minutes’ time. Please watch the demonstration video to the right to learn more.

How to store the VANTAS implant (refrigeration required)

VANTAS is supplied in a carton containing 2 inner cartons, one for the VANTAS implant, which requires refrigeration, and one for the VANTAS implantation kit, which does not require refrigeration.

Upon receipt:

Remove implant packaging from foam container in the shipping carton.
The implant requires refrigeration. Store the unopened glass vial in a refrigerator at 2º to 8ºC/36º to 46ºF (do not freeze) until day of procedure.
VANTAS is to be implanted before the expiration date printed on the carton and the vial. The insertion kit, which is boxed separately, does not require refrigeration.

Important Safety Information

VANTAS is contraindicated in women, pediatric patients and patients with hypersensitivity to GnRH, GnRH agonist analogs, or any of the other components of VANTAS.

VANTAS, like other LHRH agonists, causes a transient increase in serum concentrations of testosterone during the first week of treatment. Patients may experience worsening of symptoms or onset of new symptoms, including bone pain, neuropathy, hematuria, or ureteral or bladder outlet obstruction, cases of ureteral obstruction and spinal cord compression. Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.

Implant insertion and removal is a surgical procedure and should use aseptic technique. Careful adherence to the recommended insertion and removal procedures is recommended. In all clinical trials combined, an implant was not recovered in 8 patients, 2 of these 8 patients had serum testosterone levels above castrate level and the implant was not visualized with ultrasound. In all of the 8 patients, the implant was not palpable.

Response to VANTAS should be monitored measuring serum concentrations of testosterone and PSA periodically.

In clinical trials, the most common adverse reactions were hot flashes, fatigue, and implant site reaction. During post-marketing surveillance, rare cases of pituitary apoplexy have been reported after the administration of GnRH agonists.

Chart your patients’ course with a once-yearly administration

How to store the VANTAS implant (refrigeration required)

Click here for a larger view

Important Safety Information

Chart your patients’ course with
a once-yearly administration